UNSPSC 51295103: Dazadrol

This classification denotes an antidepressant agent with the molecular formula C15H14CLN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9U27285V5R chemically known as 2-pyridinemethanol, .alpha.-(4-chlorophenyl)-.alpha.-(4,5-dihydro-1h-imidazol-2-yl)- but generally known as dazadrol, which bears US NIH Compound Identifier 32940. European Medicines Agency schedules Dazadrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06918MIG.

UNSPSC 51295103 Dazadrol is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities — Seminole County's procurement of naloxone and drug deactivation systems, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products — involve pharmaceutical distribution, pharmacy benefit management, and opioid-response supplies, but not dazadrol specifically. The code shows minimal relevant recent activity; state and local agencies soliciting pharmaceutical products are using broader family or class-level codes rather than this narrow commodity designation, or the tagging reflects a data-entry error rather than the actual procurement scope.

Geographic activity spans Florida (Seminole County), Texas (state HHS commission), and Minnesota with participating jurisdictions including Oregon, representing fragmented state-level and county-level procurement across health and human services functions. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas RFI (HHS0017013, posted April 3, 2026) explored direct-to-manufacturer prescription capabilities; and the MMCAP RFP (S1070000015802, due March 26, 2026) established multi-state contracts for generic pharmaceuticals and OTC products through three authorized wholesalers. None of these solicitations explicitly reference dazadrol, and the code itself appears inactive or misapplied in current state and local procurement practice.